Tools   Select Another Resource Report Type

http://www.lifelines.net/

Overall aim of the LifeLines Study is to unravel the interaction between genetic and environmental factors in the development of multifactorial diseases, their concurrent development in individuals and their complications as a complex trait. The LifeLines database contains questionnaire data, physical measurements and biological samples from different health examinations. Collaboration is encouraged as it helps to maximize the scientific value of the wealth of epidemiologic data made possible by the participation of more than 165,000 individuals in the LifeLines Cohort Study. Primary objectives of the LifeLines Cohort Study are: a. Which are the disease overriding risk factors which predict the development of a multifactorial disease during lifetime? b. How are these universal risk factors modified, or what determines the effect of a universal risk factor in an individual? Specific research questions will focus on risk factors and modifiers (genetic, environmental and combined or complex factors) for single and multiple diseases. In addition to co-morbidity, LifeLines focuses on co-determinants. The primary endpoints include measures of aging, metabolic and endocrine diseases, cardiovascular and renal diseases, pulmonary and musculoskeletal diseases, and psychopathology. Secondary aims include the assessment of the prevalence and incidence of multifactorial diseases, their risk factors and their treatment in individuals as well as in families. The burden of disease for the society will be quantified in terms of care needed, and total costs of care. Until November 3, 2011, almost 68,000 subjects have been included in the study. The 60,000th participant was screened in the beginning of September 2011. Recruitment rate at present is between 700 and 800 subjects per week. The laboratory measurements which are performed has changed. As of October 2011, LifeLines will continue to measure: hematologic parameters, including hemoglobin, white blood cells, platelets, WBC differentiation, blood glucose, cholesterol, HDL-cholesterol, triglycerides, serum creatinin and sodium/potassium. Liver enzymes, thyroid hormones, calcium, phosphate, albumin, uric acid and microalbuminuria will not be measured routinely. The samples that are available for almost all participants, are: # serum (taken either with or without gel separator) # EDTA plasma # citrate plasma # DNA # early morning urine sample # urine samples of 24-hour urine collection Any researcher who is member of an internationally recognized academic institution and who is interested in utilizing the research possibilities, data and materials of LifeLines may apply for access. The applicant who is acting as Principal Investigator must be connected to a department or institution with the competence to carry out the research project to term. A contract will give the right to use the data for a pre-determined period of time. This contract also comprises the costs for the LifeLines Biobank which the investigator needs to reimburse. To apply for access, refer to the electronic application process.

Proper citation: Lifelines Biobank (RRID:SCR_010730) Copy   

•   Source: SciCrunch Registry

https://www.urmc.rochester.edu/microbiology-immunology/xenopus-laevis.aspx

A comprehensive resource specializing in the use of the amphibian Xenopus laevis (the African clawed frog) for biomedical and immunological research. Several genetically-defined inbred strains and clones are available for study. The facility also maintains and develops research tools such as transgenic animals, monoclonal antibodies, cell lines, DNA libraries, and molecular probes. XLRR includes a satellite facility devoted to study infectious diseases caused by iridovirus. Technical assistance, education, and training are also provided.

Proper citation: Xenopus laevis Research Resource for Immunobiology (XLRR) (RRID:SCR_014354) Copy   

•   Source: SciCrunch Registry

https://www.med.upenn.edu/gtp/vectorcore/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 1, 2023. A full service viral vector core facility located at the University of Pennsylvania. This facility provides technological resources for investigators in their use of viral based vectors for gene transfer. The main objective of this core is to provide investigators with state-of-the-art vector technology for preclinical studies and other basic research applications, that will then increase understanding of gene function and the further development of therapeutic vectors.

Proper citation: Vector Core (RRID:SCR_014475) Copy   

•   Source: SciCrunch Registry

http://www.flinders.edu.au/sabs/fcas/alsa/alsa_home.cfm

The general purpose of ALSA is to examine how social, biomedical, psychological, economic, and environmental factors are associated with age-related changes in the health and wellbeing of persons aged 70 years and older. The aim is to analyze the complex relationships between individual and social factors and changes in health status, health care needs and service utilization dimensions, with emphasis given to the effects of social and economic factors on morbidity, disability, acute and long-term care service use, and mortality. The study was designed to have common instrumentation with US studies. ALSA collected data from a random, stratified sample of all persons (both community and institution-dwelling) aged 70 years and older living in the metropolitan area of Adelaide, South Australia, using the State Electoral Database as the sampling frame. Spouses aged 65 and older and other household members aged 70 years and older also were invited to participate. The initial baseline data collection for ALSA began in September 1992 and was completed in March 1993. In the first wave, personal interviews were carried out for 2,087 participants, including 566 couples (that is, persons 70 years of age and over and their spouse, if 65 and over). Clinical assessments were obtained for 1,620 of the participants. Respondents were recontacted by telephone a year after initial interview (wave 2). The third wave of the study began in September 1994 and involved a complete reassessment, with a total of 1,679 interviews and 1,423 clinical assessments. To date, eleven waves of data have been collected, with the latest collection in May 2010, from 168 participants. Six of these waves were conducted via face-to-face interviews and clinical assessments, and five were telephone interviews. Future waves are planned, however are dependent on grant funding. Ancillary data collection has been ongoing since the initiation of the study, e.g., from secondary providers. Lists of ALSA participants are compared biannually with the agencies'' lists to determine the prevalence and incidence of receipt of services from these organizations. Another source of information has been the collection of data from the participants'' general practitioners about the respondent''s health status, history of services received, medication use, referrals to specialists, and current services provided. Baseline Sample Size: 2087 Dates of Study: 1992����������2010 (potentially ongoing) Study Features: * Longitudinal * International * Anthropometric Measures * Biospecimens Waves 1-5 (ICPSR), http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/06707 Wave 6 (ICPSR), http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/03679

Proper citation: ALSA - The Australian Longitudinal Study of Ageing (RRID:SCR_013146) Copy   

•   Source: SciCrunch Registry

http://www.uchicagoddrcc.org/research-cores/tissue-engineering-and-cell-models-core

Core that provides services such as a repository for intestinal cell lines, Tissue Engineering Models, experimental materials, and supplies for digestive disease research.

Proper citation: University of Chicago Digestive Diseases Research Core Center Tissue Engineering and Cell Models Core (RRID:SCR_015604) Copy   

•   Source: SciCrunch Registry

http://www.tcd.ie/IMM/trinity-biobank/index.php

The Trinity Biobank was established in 2005 to serve the needs of researchers in the area of genetic epidemiology, population genetics and pharmacogenomics. Its services are available to researchers not only in Trinity College but to other institutions at home and abroad. We provide an automated DNA extraction service purifying large volumes blood (up to 10mL whole blood) and tissue DNA for archival and other purposes. In addition it makes available purified DNA and associated GWAS data from 2000 healthy donors for research use. A key requirement for reliable downstream use of DNA is purity and strand size. The quality of DNA in blood and tissue deteriorates upon storage without purification even at -80 degrees C. We ensure rapid turnaround of biological samples through automated extraction using the Qiagen Autopure system based on optimized ''salting out'' chemistry. The purified DNA sample may then be stored safely at -20 degrees C without deterioration thus freeing up valuable -80 degree C freezer space and the associated capital and maintenance cost as well as security and lab space provision. Automated DNA extraction is particularly suitable for high-throughput sample processing called for in epidemiological studies or simply for clearing sample inventory backlogs. The Trinity Biobank distributes control DNA to researchers as part of its remit to enhance the level of research activity and to synergize molecular medicine research nationally and internationally. The buffy coat collection has been made possible with the cooperation of the Irish Blood Transfusion Service (IBTS). An important requirement to access the collection is that the use of the samples relates only to ethically-approved research and to specifically-nominated research projects. The DNA collection consists of high quality human genomic DNA. Each of the available 2,000 samples is from a single individual and each sample comes with the age and gender data of the donor. The buffy coat sample is derived from the total white cell compliment (50mL buffy coat) of a blood donation (c 400mL). We will endeavor to fulfill samples number requests based on age and gender as best as possible. This collection has also been genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0, featuring 1.8 million genetic markers, including more than 906,600 single nucleotide polymorphisms (SNPs) and more than 946,000 probes for the detection of copy number variation (CNV). The DNA comes available as a 100ng/uL in 100uL of TE Buffer, ie in 10ug amounts in a separate screw-cap ampoule. The ampoules are shipped in 100-tube boxes (Sarstedt). Corresponding plasma (ACD) is also available on request. Genotype data is supplied in PLINK binary PED files format (http://pngu.mgh.harvard.edu/~purcell/plink/ ).

Proper citation: Trinity Biobank (RRID:SCR_013279) Copy   

•   Source: SciCrunch Registry

http://www.cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/

A prospective observational national cohort study poised to make fundamental insights into the epidemiology, management, and outcomes of chronic kidney disease (CKD) in adults with intended long-term follow up. The major goals of the CRIC Study are to answer two important questions: * Why does kidney disease get worse in some people, but not in others? * Why do persons with kidney disease commonly experience heart disease and stroke? The CRIC Scientific and Data Coordinating Center at Penn receives data and provides ongoing support for a number of Ancillary Studies approved by the CRIC Cohort utilizing both data collected about CRIC study participants as well as their biological samples. The CRIC Study has enrolled over 3900 men and women with CKD from 13 recruitment sites throughout the country. Following this group of individuals over the past 10 years has contributed to the knowledge of kidney disease, its treatment, and preventing its complications. The NIDDKwill be extending the study for an additional 5 years, through 2018. An extensive set of study data is collected from CRIC Study participants. With varying frequency, data are collected in the domains of medical history, physical measures, psychometrics and behaviors, biomarkers, genomics/metabolomics, as well as renal, cardiovascular and other outcomes. Measurements include creatinine clearance and iothalamate measured glomerular filtration rate. Cardiovascular measures include blood pressure, ECG, ABI, ECHO, and EBCT. Clinical CV outcomes include MI, ischemic heart disease-related death, acute coronary syndromes, congestive heart failure, cerebrovascular disease, peripheral vascular disease, and composite outcomes. The CRIC Study has delivered in excess of 150,000 bio-samples and a dataset characterizing all 3939 CRIC participants at the time of study entry to the NIDDKnational repository. The CRIC Study will also be delivering a dataset to NCBI''''s Database for Genotypes and Phenotypes.

Proper citation: Chronic Renal Insufficiency Cohort Study (RRID:SCR_009016) Copy   

•   Source: SciCrunch Registry

http://www.bonebank.com

Biotechnology company dedicated to enhancing quality of patient care through development and manufacture of safe, high quality allograft solutions for healthcare professionals.

Proper citation: Texas Human Biologics (RRID:SCR_010523) Copy   

•   Source: SciCrunch Registry

http://www.salk.edu/science/core-facilities/media-preparation-core/

Core facility that provides media, plates, and commonly used buffers for molecular biology applications and culturing mammalian cells, C. elegans, yeast, and bacteria. The Media Preparation Core Facility is equipped with 3 automatic plate pourers supported by 2 programmable media kettles capable of producing up to 9 liters of agar or nutrient media per run under gentle and reproducible conditions. Plates are available in 6 cm or 10 cm formats.

Proper citation: Salk Institute Media Preparation Core Facility (MPRP) (RRID:SCR_014844) Copy   

•   Source: SciCrunch Registry

https://www.lifegene.se/In-english/

Swedish study to get a better understanding of how genes, environment and way of life affect health that will enable access to the longitudinal data on 500,000 participants after ethical approval. Half a million people in Sweden between the ages of 0 and 45 will be recruited as volunteers for 6 to 8 years. People between 18 and 45 will be invited and they may, in turn, bring children and other people that they live with into the project. Participants will be followed for many years with regular online surveys and health checks. Their blood and urine samples will also be stored in a biobank. All the data will form a very large information base, where researchers can follow what happens with people''''s health. The LifeGene test center will measure height, hip, waist and chest measurements. A so-called spirometry test will be conducted which measures lung function, a hearing test and bioimpedance measurement (includes weight, BMI and distribution of body fat and muscle mass). They also take blood and urine samples and measure blood pressure and pulse. LifeGene foresees a lot of different research cooperation. Everything from simple withdrawal of longitudinal data, leverage of LifeGene infrastructure and cooperation between LifeGene and complementing scientific projects covering specific areas in more depth. LifeGene will enable access to unique longitudinal data on 500,000 participants available for researchers after ethical approval. LifeGene is also an infrastructure with Test Centers covering most of Sweden, logistics for sample management from arm-to-freezer and state-of-the-art large scale automatic biobanking enabling low cost, high quality, fast withdrawal of biological samples.

Proper citation: LifeGene (RRID:SCR_010524) Copy   

•   Source: SciCrunch Registry

http://www.psbc.org/home/index.htm

At Puget Sound Blood Center, when we talk about the work of our Research Institute, what we are really talking about is saving lives. Many recognize the lifesaving work of the Blood Center for its role in maintaining the blood supply for Western Washington. But that is only the beginning of how the Blood Center touches the lives of people all over the world. The Blood Center is widely considered the premier knowledge source on blood research and transfusion medicine and has been developing cutting-edge technologies and establishing best practices in this field for over sixty-six years. Medical institutions worldwide rely on the Blood Center''s research work. Scientific equipment manufacturers, as well as pharmaceutical companies turn to the Blood Center for help in developing effective equipment and successful therapies that are saving lives around the world every day.

Proper citation: Puget Sound Blood Center (RRID:SCR_010527) Copy   

•   Source: SciCrunch Registry

http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/clinical-departments/pathology/research/oregon-brain-bank.cfm

Brain bank that harvests, banks and disperses postmortem tissue for use in brain and medical research. It also provides neuropathologic diagnoses of organic dementia in a cohort of NIH sponsored research subjects. The bank includes tissue primarily from patients with Alzheimer's but also includes Huntington's, Parkinson's, and other disorders.

Proper citation: Oregon Brain Bank (RRID:SCR_013085) Copy   

•   Source: SciCrunch Registry

http://www.sbpdiscovery.org/technology/sr/Pages/LaJolla_StemCells.aspx

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. The former functions of this facility are split into two separate operations. The first is the generation and characterization of induced Pluripotent Stem Cells (iPSCs) is now being performed on a collaborative basis for both internal and external investigators with the Snyder lab. The second is a shared laboratory dedicated to the culture and analysis of stem cells that is available to SBP investigators.

Proper citation: Sanford Burnham Prebys Medical Discovery Institute Stem Cell Core (RRID:SCR_014856) Copy   

•   Source: SciCrunch Registry

http://www.jcm.riken.go.jp/

The Microbe Division in RIKEN-BRC has been collecting, preserving, and distributing cultured microbial strains as one of the leading culture collections in the world since established as Japan Collection of Microorganisms (JCM) in 1981. JCM aims to contribute to scientific communities by maintaining and serving high-quality microbial resources useful for general microbial studies and various research fields particularly in health and environmental science. JCM has participated in the National BioResource Project supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan as the core facility for General Microbes. JCM maintains approximately 19,900 strains as of Sept. 2010, and the approximate numbers of the available strains from JCM are: 7,400 strains of aerobic and anaerobic bacteria including actinomycetes, 300 strains of archaea, and 4,100 strains of fungi including yeasts (in total ca. 12,000 strains). Strains held at JCM are limited to those classified in Risk Group 1 or 2. Information of the available strains is opened to the public through the JCM On-line Catalogue Database. Genomic DNA samples of some strains are also distributed in cooperation with RIKEN BRC-DNA Bank. More than 3,500 strains are annually distributed to domestic and overseas researchers. JCM welcomes a deposit of microbial strains published or designed to be published in scientific papers as well as an order for microbial cultures.

Proper citation: JCM (RRID:SCR_010653) Copy   

•   Source: SciCrunch Registry

http://www.psoriasis.org/netcommunity/act_biobank

The National Psoriasis Victor Henschel BioBank is a collection of biological samples and clinical information used by qualified scientists to further the field of psoriasis genetics. Once completed, the National Psoriasis BioBank will be the largest collection of psoriasis DNA samples in the world, moving us closer to understanding the causes of psoriatic diseases, discovering more and better treatments and finding a cure. The BioBank is currently collecting DNA from people with and without psoriasis and/or psoriatic arthritis. Simply by donating your DNA����??a blood sample and a swab of your cheek cells����??and providing us with your medical history, you can help us find a cure. Samples will be processed and stored at a private laboratory and not at the National Psoriasis Foundation. The National Psoriasis BioBank is part of the Genetic Alliance BioBank (GA BioBank), a centralized repository for the collection, storage and distribution of biological samples (including DNA, serum, cells and tissues) and clinical data for genetic researchers.

Proper citation: National Psoriasis BioBank (RRID:SCR_010537) Copy   

•   Source: SciCrunch Registry

http://www.sbpdiscovery.org/technology/sr/Pages/LaJolla_TumorAnalysis.aspx

Facility that provides analysis of animal models of human cancer and other diseases. It provides investigators access to a wide variety of human cancer cell lines for xenograft studies, some primary human xenograft models and additional transgenic mouse solid tumors and leukemia models. The core also offers serial passaging of tumors and derivation of 2D and 3D cultures from xenograft tumors, including patient-derived xenograft (PDX) models. These short-term cell cultures established from PDXs enable in vitro analysis including high throughput screening with compounds or RNAi for functional characterization.

Proper citation: Sanford Burnham Prebys Medical Discovery Institute Tumor Analysis (RRID:SCR_014858) Copy   

•   Source: SciCrunch Registry

http://www.eurobiobank.org/en/partners/description/inncb_copy.htm#organisation

A biobank of human biological material and genetic information. It provides samples and information to researchers in order to identify new genes and clarify pathogenic mechanisms of diseases. The biobank offers biochemical and molecular diagnoses of genetic dystonias, Parkinson's disease and NBIA disorders, as well as storage of biological samples for external institutions.

Proper citation: Movement Disorders Biobank (RRID:SCR_010659) Copy   

•   Source: SciCrunch Registry

https://github.com/NCBI-Hackathons/PhenVar

Software tool used to generate a list of PubMed IDs to query and generate associations between publications. It utilizes a local SQLite cache in a configurable location to keep a local copy of relevant SRIDs, PMIDs, and the Abstract sections for the PMIDs.

Proper citation: PhenVar (RRID:SCR_015515) Copy   

•   Source: SciCrunch Registry

http://sites.duke.edu/dhhr/

A biomaterial supply resource which collects and disseminates human heart tissue. Samples include both failing and non-failing hearts, RNA/DNA analysis, tissue staining and immunofluorescence samples.The tissue that has been flash frozen and stored at -80˚C is acquired from distinct regions of the heart such as the LV free wall, septum, and valve leaflets. Individual sample sizes are typically 100-300mg for flash frozen tissues. The DHHR also serves as a resource for assay development, target identification, and sponsored research, capable of isolating cardiomyocytes from hearts and using them for in-vitro assays such as calcium handling, enzyme activity, signalling pathways and other biochemical research activities

Proper citation: Duke Human Heart Repository (RRID:SCR_013980) Copy   

•   Source: SciCrunch Registry

http://www.yerkes.emory.edu/about/news/neuropharmacology_neurologic_diseases/Transgenic_Huntingtons_Disease_Monkey_Resource_Available.html

Center for resources to facilitate basic and preclinical applications of the transgenic Huntington's disease (HD) monkey model to advance scientific knowledge and the discovery of a cure for HD. Their resources include longitudinal biomaterials and MRI data, postmortem biomaterials, and research proposal assistance.

Proper citation: Transgenic Huntington's Disease Monkey Resources (RRID:SCR_014560) Copy   

•   Source: SciCrunch Registry